LU91204I2 - Pegvisomant, facultativement sous forme d'une variante de pégylation - Google Patents

Pegvisomant, facultativement sous forme d'une variante de pégylation

Info

Publication number
LU91204I2
LU91204I2 LU91204C LU91204C LU91204I2 LU 91204 I2 LU91204 I2 LU 91204I2 LU 91204 C LU91204 C LU 91204C LU 91204 C LU91204 C LU 91204C LU 91204 I2 LU91204 I2 LU 91204I2
Authority
LU
Luxembourg
Prior art keywords
pegvisomant
optionally
growth hormone
variants
disclosed
Prior art date
Application number
LU91204C
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91204(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of LU91204I2 publication Critical patent/LU91204I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
LU91204C 1995-09-21 2005-10-28 Pegvisomant, facultativement sous forme d'une variante de pégylation LU91204I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53706895A 1995-09-21 1995-09-21
US53706795A 1995-09-21 1995-09-21
PCT/US1996/014830 WO1997011178A1 (fr) 1995-09-21 1996-09-20 Variants de l'hormone de croissance humaine

Publications (1)

Publication Number Publication Date
LU91204I2 true LU91204I2 (fr) 2006-02-06

Family

ID=27065361

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91204C LU91204I2 (fr) 1995-09-21 2005-10-28 Pegvisomant, facultativement sous forme d'une variante de pégylation

Country Status (13)

Country Link
US (4) US5849535A (fr)
EP (3) EP1568772B1 (fr)
JP (2) JP3628333B2 (fr)
AT (2) ATE455171T1 (fr)
AU (1) AU718439B2 (fr)
CA (2) CA2230492C (fr)
DE (5) DE69635026T2 (fr)
DK (2) DK1568772T3 (fr)
ES (2) ES2190388T3 (fr)
LU (1) LU91204I2 (fr)
NL (1) NL300210I2 (fr)
PT (1) PT1568772E (fr)
WO (1) WO1997011178A1 (fr)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6946265B1 (en) 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
AU5132900A (en) * 1999-05-12 2000-11-21 Xencor, Inc. Novel nucleic acids and proteins with growth hormone activity
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
DE10005301A1 (de) * 2000-02-07 2001-08-09 Trutnau Hans Heinrich Multi-Schritt-Kinetik molekularer Interaktionen als analytisches Mess- und Auswerte-Verfahren
GB0011459D0 (en) * 2000-05-12 2000-06-28 Univ Wales Medicine Sequences
WO2001085993A2 (fr) * 2000-05-12 2001-11-15 University Of Wales College Of Medicine Procede de detection de variations d'hormones de croissance chez des etres humains, variations et utilisations associees
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
EP1290170A2 (fr) 2000-06-16 2003-03-12 Asterion Limited Liant
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
KR20030038690A (ko) * 2000-08-07 2003-05-16 인헤일 테라퓨틱 시스템즈 인크. 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002055532A2 (fr) * 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
CA2449647A1 (fr) * 2001-06-05 2002-12-12 Auckland Uniservices Limited Methodes et compositions permettant l'evaluation de la fonction et des troubles pulmonaires
US7521175B2 (en) 2001-06-14 2009-04-21 The Regents Of The University Of California Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CA2461292A1 (fr) 2001-10-02 2003-04-10 Genentech, Inc. Variants de ligands apo-2 et leurs utilisations
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305312B1 (fr) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US20040161802A1 (en) * 2001-10-30 2004-08-19 Applied Molecular Evolution Methods for producing and improving therapeutic potency of binding polypeptides
MXPA04004291A (es) * 2001-11-09 2004-08-11 Upjohn Co Polimorfismos de un unico nucleotido en la gh-1.
EP1444262A2 (fr) * 2001-11-12 2004-08-11 University of Wales College of Medicine Variations de l'hormone de croissance chez les humains et leurs utilisations
HRP20040448A2 (en) * 2001-11-20 2006-02-28 Pharmacia Corporation Method for detecting cells with numerical chromosomal abnormalities
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
RU2216346C1 (ru) * 2002-06-10 2003-11-20 Семенова Наталья Викторовна Средство и способ для биогенной стимуляции организма
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US20040048315A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
DE60330787D1 (de) * 2002-09-20 2010-02-11 Pharmacia Corp Verfahren zur verringerung der aggregatmengen des pegylierten proteins
US7470779B2 (en) * 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
NZ525314A (en) * 2002-12-19 2005-02-25 Univ Cardiff Method and kit for diagnosing growth hormone dysfunction by determining SNP haplotypes of the proximal promoter region of the gene GH1
DK1581251T3 (da) * 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
WO2004090135A2 (fr) * 2003-04-09 2004-10-21 Asterion Limited Polypeptides contenant du glycosylphosphatidylinositol
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (fr) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Facteur ix glycopegyle
EP1615945B1 (fr) * 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
WO2004091499A2 (fr) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Formation intracellulaire de conjugues de peptides
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
MXPA05011832A (es) 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
EP2003196A3 (fr) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions et procédés de diagnostic et de traitement des cancers
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
AU2004293103C1 (en) * 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1694274B1 (fr) * 2003-12-03 2013-04-24 BioGeneriX AG Facteur de stimulation de colonies de granulocytes glycopegylé
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
NZ548513A (en) * 2004-01-14 2010-05-28 Univ Ohio Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
EP2368579A1 (fr) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Conjugaison au moyen de transglutaminase de peptides
US8778880B2 (en) * 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
WO2005074633A2 (fr) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
EP1715895A2 (fr) * 2004-02-09 2006-11-02 Pharmacia Corporation Conjugues antagonistes du recepteur de l'hormone de croissance humaine chimiquement modifies
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2573918A1 (fr) 2004-04-19 2005-11-24 Ohio University Glycoproteines reticulables et leurs methodes de fabrication
EP1751115A4 (fr) 2004-05-23 2010-10-20 Gerard M Housey Modulateurs de theramuteine
CA2558760A1 (fr) * 2004-06-23 2006-01-05 Usv Limited Hormone de croissance humaine chimerique derivee de placenta et d'isoformes hypophysaires et processus permettant d'obtenir cette chimere
US8124653B2 (en) 2004-06-25 2012-02-28 The Board Of Regents Of The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
WO2006010891A2 (fr) * 2004-07-26 2006-02-02 Asterion Limited Lieurs
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1799249A2 (fr) 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
WO2006042848A2 (fr) * 2004-10-18 2006-04-27 Novo Nordisk A/S Conjugues d'hormones de croissance
EP1814573B1 (fr) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
WO2006071840A2 (fr) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2284191A3 (fr) * 2004-12-22 2011-07-20 Ambrx, Inc. Procédé de préparation de hGH
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
CA2593682C (fr) 2005-01-10 2016-03-22 Neose Technologies, Inc. Facteur de stimulation de colonie de granulocytes glycopegylatees
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP1861125A2 (fr) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugues d'un fragment de hgh et d'un polymere
WO2006102542A2 (fr) * 2005-03-23 2006-09-28 Bio-Rad Laboratories, Inc. Bibliotheques chimiques diverses associees a de petites particules presentant des propriete paramagnetiques
US20090247421A1 (en) * 2005-03-23 2009-10-01 Egisto Boschetti Diverse chemical libraries bound to small particles with paramagnetic properties
JP4841618B2 (ja) * 2005-03-23 2011-12-21 バイオ−ラッド ラボラトリーズ インコーポレーティッド タンパク質を精製するための方法
EP1866427A4 (fr) * 2005-03-30 2010-09-01 Novo Nordisk As Procede de fabrication pour la production de peptides cultives dans des lignees cellulaires d'insectes
EP1871795A4 (fr) * 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
CN101163505A (zh) * 2005-04-13 2008-04-16 伊拉斯谟大学鹿特丹医药中心 使用gh拮抗剂和生长抑素激动剂的治疗方法
EP1896607A4 (fr) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd Procédés et compositions pour l'évaluation de la fonction et de troubles pulmonaires
MX2007014220A (es) * 2005-05-19 2009-02-16 Synergenz Bioscience Ltd Metodos para la valoracion del riesgo de desarrollar cancer de pulmon usando un analisis de polimorfismos geneticos.
EP1888779A4 (fr) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Méthodes d'analyse de polymorphismes et leurs utilisations
US8431110B2 (en) * 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP1888098A2 (fr) 2005-05-25 2008-02-20 Neose Technologies, Inc. Formulations d'erythropoietine glycopegylees
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007008708A2 (fr) * 2005-07-08 2007-01-18 Ohio University Methodes destinees a predire des sites de glycosylation de hyp pour des proteines exprimees et secretees dans des cellules vegetales, et methodes et produits associes
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007041614A2 (fr) * 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
WO2007062213A2 (fr) 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Composes et procedes d’identification, de synthese, d’optimisation et de creation de profils de modulateurs de proteines
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP2009521486A (ja) * 2005-12-23 2009-06-04 アルタス ファーマシューティカルズ インコーポレイテッド ポリカチオン錯化タンパク質結晶を含む組成物およびこれを使用した治療法
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
WO2007100640A2 (fr) * 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Traitement du cancer a l'aide d'antagonistes du recepteur de l'hormone de croissance
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP2044246A4 (fr) * 2006-07-06 2009-12-16 Molecular Logix Inc Système de découverte de médicaments à ligand dominant négatif
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CA2665480C (fr) * 2006-10-04 2019-11-12 Novo Nordisk A/S Glycopeptides et sucres pegyles a liaison glycerol
WO2008073620A2 (fr) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Procédé de fabrication pour la production de polypeptides exprimés dans des lignées cellulaires d'insectes
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2102355B1 (fr) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
WO2008092002A2 (fr) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009036349A1 (fr) * 2007-09-12 2009-03-19 Anaphore, Inc. Traitement à base de hsp70 pour maladies auto-immunitaires
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
CA2705160A1 (fr) * 2007-11-09 2009-05-14 Anaphore, Inc. Proteines de fusion de lectines liant le mannose pour un traitement de maladie
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
EP3412300A1 (fr) 2008-06-27 2018-12-12 Duke University Agents thérapeutiques comprenant des peptides de type élastine
WO2010014225A2 (fr) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Dosages permettant la détection de la phénylalanine ammoniac-lyase et des anticorps contre la phénylalanine ammoniac-lyase
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
EP2379585A2 (fr) 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides qui se lient à trail-ri et trail-r2
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8445953B2 (en) * 2009-07-08 2013-05-21 Taiwan Semiconductor Manufacturing Company, Ltd. Structure for flash memory cells
WO2011015649A1 (fr) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Hormones de croissance ayant une efficacité in vivo prolongée
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
EP2332929A1 (fr) 2009-11-25 2011-06-15 ArisGen SA Dérivés d'orthoester d'éthers couronne comme vehicules pour compositions diagnostiques et pharmaceutiques
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20130045215A1 (en) 2010-04-28 2013-02-21 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
US20130143815A1 (en) 2010-07-22 2013-06-06 Novo Nordisk Health Care Ag Growth hormone conjugates
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
WO2012151317A1 (fr) 2011-05-03 2012-11-08 Genentech, Inc. Agents d'interruption vasculaire et utilisations associées
EP2526971A1 (fr) 2011-05-25 2012-11-28 ArisGen SA Administration de médicaments par les muqueuses
WO2013113074A1 (fr) 2012-02-03 2013-08-08 Antisense Therapeutics Ltd Polythérapie comprenant un variant de l'hormone de croissance et un oligonucléotide ciblant le récepteur de l'hormone de croissance
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
WO2014139994A1 (fr) * 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Composés d'hormone de croissance
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014144231A1 (fr) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Utilisation d'antagonistes de l'hormone de croissance ou de recepteur de l'hormone de croissance pour empecher ou traiter une maladie psychiatrique sensible au stress
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
CA2920666A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Compositions et methode pour le traitement de troubles associes au complement
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
CN104693433B (zh) * 2015-02-04 2017-06-06 国家纳米科学中心 一种聚乙二醇化氨磷汀、制备方法及其用途
WO2016138099A1 (fr) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Utilisation de ghréline ou d'agonistes fonctionnels des récepteurs de la ghréline pour prévenir et traiter une maladie psychiatrique sensible au stress
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (fr) 2015-10-01 2024-06-26 Novo Nordisk A/S Conjugués de protéines
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
GB201520021D0 (en) 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
WO2019125002A1 (fr) * 2017-12-20 2019-06-27 (주)알테오젠 Nouvel antagoniste du récepteur de l'hormone de croissance et sa protéine de fusion
WO2019211842A1 (fr) * 2018-04-30 2019-11-07 Opko Biologics Ltd. Antagonistes de l'hormone de croissance humaine à action prolongée et leurs procédés de production
CA3141128A1 (fr) * 2019-06-17 2020-12-24 Molecular Technologies Laboratories Llc Antagonistes therapeutiques d'hormone de croissance pegylee
US11999787B2 (en) 2020-03-24 2024-06-04 Genentech, Inc. Tie2-binding agents and methods of use
WO2023004687A1 (fr) * 2021-07-29 2023-02-02 浙江新码生物医药有限公司 Acide aminé non naturel et son utilisation, protéine recombinante le contenant et conjugué de protéine recombinante
US20240317832A1 (en) * 2021-07-29 2024-09-26 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate
AU2023314508A1 (en) 2022-07-29 2024-11-14 University Of Rochester Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
AU2024272220A1 (en) 2023-05-12 2025-10-16 Novo Nordisk A/S Long-acting growth hormone receptor antagonist and use thereof
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법
WO2025259466A1 (fr) 2024-06-13 2025-12-18 University Of Rochester Cellules dendritiques induites par gm-csf et gm-csf améliorant la cicatrisation de fractures et la réparation osseuse

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853832A (en) * 1971-04-27 1974-12-10 Harmone Res Foundation Synthetic human pituitary growth hormone and method of producing it
US3853833A (en) * 1971-04-27 1974-12-10 Hormone Res Foundation Synthetic human growth-promoting and lactogenic hormones and method of producing same
US4880910A (en) * 1981-09-18 1989-11-14 Genentech, Inc. Terminal methionyl bovine growth hormone and its use
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4665160A (en) * 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (bg) * 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
AU615194B2 (en) * 1987-03-12 1991-09-26 Amgen, Inc. Bovine growth hormone analogs
DE3877300T2 (de) * 1987-04-02 1993-06-03 Genentech Inc Substratunterstuetzte katalyse.
EP1541682A3 (fr) * 1988-09-02 2005-07-06 Dyax Corp. Production et sélection de protéines de liaison diversifiées recombinantes
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
CA2345497A1 (fr) * 1988-10-28 1990-04-28 Genentech, Inc. Variantes de l'hormones de croissance et procede de fabrication des variantes de l'hormone de croissance
JPH04503154A (ja) * 1988-11-07 1992-06-11 ルニベルシー・ド・ルタ・ア・リージュ 変型ヒト成長ホルモン
AU620673B2 (en) * 1989-01-31 1992-02-20 Pharmacia & Upjohn Company Somatotropin analogs
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JPH06507632A (ja) * 1991-05-01 1994-09-01 オハイオ ユニバーシティー 成長ホルモンアンタゴニスト
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
WO1995008571A1 (fr) * 1993-09-22 1995-03-30 American Cyanamid Company Somatotropine porcine ayant une stabilite accrue et son procede de production
AU5881996A (en) * 1995-06-07 1996-12-30 Ohio University/Edison Biotechnology Institute Methods of treatment using growth hormone antagonists
WO1996040731A1 (fr) * 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Proteines modifiees conjuguees a du polyethylene-glycol (peg)

Also Published As

Publication number Publication date
US5849535A (en) 1998-12-15
JP2005021157A (ja) 2005-01-27
US6004931A (en) 1999-12-21
JP3628333B2 (ja) 2005-03-09
DE69635026D1 (de) 2005-09-08
WO1997011178A1 (fr) 1997-03-27
ATE455171T1 (de) 2010-01-15
EP1568772B1 (fr) 2010-01-13
ATE301196T1 (de) 2005-08-15
CA2230492A1 (fr) 1997-03-27
DE69635026T2 (de) 2006-05-24
DK1568772T3 (da) 2010-10-18
DE122006000003I1 (de) 2006-05-04
EP0851925A1 (fr) 1998-07-08
AU718439B2 (en) 2000-04-13
DE122006000003I2 (de) 2011-01-13
DE851925T1 (de) 2003-08-14
PT1568772E (pt) 2010-04-14
EP1568771A2 (fr) 2005-08-31
HK1012508A1 (en) 1999-08-06
ES2338431T3 (es) 2010-05-07
EP1568772A2 (fr) 2005-08-31
JP3693668B2 (ja) 2005-09-07
NL300210I1 (nl) 2006-02-01
US6057292A (en) 2000-05-02
US6136563A (en) 2000-10-24
EP1568772A3 (fr) 2006-05-17
NL300210I2 (nl) 2007-05-01
AU7073396A (en) 1997-04-09
JPH11512298A (ja) 1999-10-26
DK0851925T3 (da) 2005-11-28
CA2658039A1 (fr) 1997-03-27
EP0851925B1 (fr) 2005-08-03
ES2190388T1 (es) 2003-08-01
CA2230492C (fr) 2009-05-26
ES2190388T3 (es) 2006-04-01
EP1568771A3 (fr) 2006-05-17
DE69638117D1 (de) 2010-03-04

Similar Documents

Publication Publication Date Title
LU91204I2 (fr) Pegvisomant, facultativement sous forme d'une variante de pégylation
DE69800640D1 (en) Pegylationsverfahren
EP0896533A4 (fr) Pentafluorobenzenesulfonamides et analogues
PH31265A (en) Aqueous solution inclusion complexes of benzo-thiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof.
IL184227A0 (en) Biologically active peptides
ITVI970167A0 (it) Struttura di copertura del posto di guida di macchine operatrici.
IT1304499B1 (it) Procedimento per ridurre il peso molecolare di copolimeri eterpolimeri dell'etilene.
EP0651035A3 (fr) Composition d'électrodéposition cationique.
EP1073447A4 (fr) Glycopeptides n1-modifies
DZ3018A1 (fr) Procédés perfectionnés pour la préparation sécrétagogues d'hormones de croissance.
AU8115287A (en) Softening detergent compositions containing specific poly-amide softening agent
GB2325466A (en) Nucleotide sequence from goat liver
ITMI922018A0 (it) Bassi polimeri dell'n-vinilpirrolidone monofunzionalizzati ad un estremo per la preparazione di coniugati con enzimi, polipeptidi farmaci
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
FR2654123B1 (fr) Solution d'agent de blanchiment fluorescent.
BR9809286A (pt) Processos para redução de fibrinogênio
IT8722543V0 (it) Cerotto, in particolare per l'impiego in corrispondenza di zone articolari.
显文 HO 2?
AU7674598A (en) Antiathlete's foot composition
KR940018814U (ko) 신의 조립식 굽
MY118694A (en) Surgeon''''s gloves from neoprene copolymers
KR940018815U (ko) 신의 조립식 굽
IT1276294B1 (it) Vetturetta per la citta' di mt. 2,10 ca.
ITRM980538A1 (it) Kit per la somministrazione di quantita' presosate di farmaci per via ionoforetica
ES555466A0 (es) Mejoras introducidas en el objeto de la patente de invencion 516.212 por perfeccionamientos introducidos en atomizadores agricolas